Ultragenyx Pharmaceutical (RARE) Downgraded to Sell at BidaskClub

Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, January 16th.

Several other equities analysts also recently weighed in on the company. Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. JPMorgan Chase & Co. restated a “buy” rating and set a $76.00 price target on shares of Ultragenyx Pharmaceutical in a report on Sunday, November 5th. Robert W. Baird reduced their price target on Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating for the company in a report on Friday, November 3rd. Cowen restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 15th. Finally, Jefferies Group upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and raised their price target for the company from $58.00 to $72.00 in a report on Monday, December 4th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $72.06.

Ultragenyx Pharmaceutical (NASDAQ RARE) traded up $4.75 on Tuesday, reaching $58.14. The company’s stock had a trading volume of 1,638,554 shares, compared to its average volume of 554,307. The company has a market capitalization of $2,480.00, a P/E ratio of -8.34 and a beta of 1.83. Ultragenyx Pharmaceutical has a twelve month low of $43.14 and a twelve month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.87). The firm had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. During the same quarter last year, the company posted ($1.64) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 81.8% compared to the same quarter last year. sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -7.31 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in Ultragenyx Pharmaceutical in the third quarter worth about $156,000. Kazazian Asset Management LLC purchased a new position in Ultragenyx Pharmaceutical in the second quarter worth about $213,000. Fox Run Management L.L.C. purchased a new position in Ultragenyx Pharmaceutical in the third quarter worth about $213,000. Ameritas Investment Partners Inc. boosted its position in Ultragenyx Pharmaceutical by 7.7% in the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares during the last quarter. Finally, Amalgamated Bank boosted its position in Ultragenyx Pharmaceutical by 7.6% in the second quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after purchasing an additional 352 shares during the last quarter. 94.10% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Ultragenyx Pharmaceutical (RARE) Downgraded to Sell at BidaskClub” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.truebluetribune.com/2018/01/24/ultragenyx-pharmaceutical-rare-downgraded-to-sell-at-bidaskclub.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply